Investigational drug · Phase 2
HB0043
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acne Vulgaris, Hidradenitis Suppurativa.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "HB0043"
First trial start
2025
Mar 19, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HB0043", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acne Vulgaris
- Hidradenitis Suppurativa
Approved drugs for the same conditions: Hidradenitis suppurativa · Acne · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "HB0043" as an intervention, largest first.
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT06999083 · 52 participants · Start Jun 3, 2025 · Primary completion Feb 12, 2026
Drug: HB0043; Placebo · For: Healthy
Sites: Auckland, New Zealand
- A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.Not yet recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT07449156 · 21 participants (planned) · Start Mar 27, 2026 · Primary completion Oct 27, 2026
Drug: HB0043; Placebo · For: Acne Vulgaris
Sites: Jinan, China
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT06895499 · 15 participants (planned) · Start Mar 19, 2025 · Primary completion Jan 30, 2026
Drug: HB0043; HB0043 and 1 more · For: Hidradenitis Suppurativa
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
- Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody.
Sun Y, Mi Z, Yu Y, et al. · Signal Transduct Target Ther 2026
- Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency.
Ma X, Zhang S, Ren X, et al. · Front Immunol 2024
Also in development for Acne Vulgaris
- DenifanstatPhase 31 trial
Sagimet Biosciences Inc. · Acne Vulgaris
- DMT310Phase 31 trial
Dermata Therapeutics · Acne Vulgaris
- B244Phase 21 trial
AOBiome LLC · Acne Vulgaris
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.